Victoria Johnson

Brensocatib, also a potential first-in-class DPP1 inhibitor, has a PDUFA date of August 12, 2025.

Despite being aware of its value in treating asthma, specialists were uncertain about integrating ITT into patient care.

This pulmonology month in review highlights recent research on diagnosing asthma and new pivotal trial data.

Frevecitinib is a novel inhaled dry powder therapeutic in development for asthma that remains inadequately controlled by SOC inhaled maintenance therapies.

The study also revealed a predominant T2-low asthma endotype in majority Puerto Rican and Black or African American youth populations.

Among multiple issues were confusing and conflicting misdiagnoses of asthma.

Peter Kranke, MD, MBA, MME, and colleagues call for clarifications to the August 2024 recommendations with more real-world considerations.

However, subgroup analyses may reveal a more pronounced effect in people with severe COPD.

CRN declined from 23.2% to 13.1% between 2011 and 2022 but still affects around 2.5 million adults in the US.

New findings cast doubt on required black box warnings for montelukast (brand name Singulair).

Meteorological conditions’ effect on exacerbations were likely mediated by particulate matter.

Current asthma diagnosis requires specialized breathing tests that can be challenging for young children.

Within 2 years of death, fall-risk increasing drug burden was associated with greater odds of an injurious fall.

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.

CT-P42 may help improve access to aflibercept in lower-income countries.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

Bendapudi gave an overview of 2 studies presented at ASH 2024 from his Harvard lab.

Rani discussed an in-depth study examining quality of sleep and quality of life in children and adolescents with SCD.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.

The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.

Celltrion’s CT-P43/ustekinumab-stba has been approved under the name Steqeyma and is expected to launch in February 2025.

Matsushita discussed findings from the OLE FRONTIER4 study of Mim8.

Matino discussed data from the phase 3 BASIS study evaluating the recently approved Hympavzi.

Samelson-Jones discussed follow-up data of up to 6 years with investigations of fidanacogene elaparvovec.

Bernaudin discussed the Drepagreffe-1 and 2 studies and improvements seen over 10 years of follow-up.